Developing at this hour- The latest ORTEX data has been released for short-squeeze candidate $ATER.
Aterian was declared a type 3 short squeeze by ORTEX.
The last three stocks to be declared a level 3 short squeeze by ORTEX?
$GME $AMC $SPRT.
Type 3 has a 55% return on average!
Exciting to say the least!!!
“ORTEX provides intra-day and historical data for days to cover, shares on loan, utilization rate, cost of borrow, and free float on loan. ORTEX also provides all relevant US exchange data and relevant institutional short holdings flags so users can access all the information available in one place.
Every day ORTEX identifies alpha-generating opportunities. These are identified through rigorous analysis and validated through back-testing. The Alpha trading signal will tell you how much return has historically been made and the optimal holding period and relative success of this signal in the past. ORTEX back-test data sets in infinite combinations and bring you the highest-ranked signals across over 50,000 stocks every day. These signals are the ones that are most likely to happen again and produce the highest return in the shortest time. ORTEX Alpha signals are split into five families Short Squeeze, EPS, RSI, MACD and Company Events. Some of these signals families have multiple types. The different types of signal look at different aspects of the metric that is the main base for that signal.”
FIND OUT MORE ABOUT THE ROCK TRADING CO!!!
Our Website is a financial data and news portal, discussion forum, and content aggregator. TRT is not a broker/dealer, we are not an investment advisor, we have no access to non-public information about publicly traded companies, and this is not a place for the giving or receiving of financial advice, advice concerning investment decisions, or tax or legal advice. We are not regulated by the Financial Services Authority.
We are an educational forum for analyzing, learning & discussing general and generic information related to stocks, investments, and strategies. No content on the site constitutes – or should be understood as constituting – a recommendation to enter in any securities transactions or to engage in any of the investment strategies presented in our site content. We do not provide personalized recommendations or views as to whether a stock or investment approach is suited to the financial needs of a specific individual.
Accordingly, we will not be liable, whether in contract, tort (including negligence), or otherwise, in respect of any damage, expense, or other loss you may suffer arising out of such information or any reliance you may place upon such information. Any arrangements between you and any third party contacted via the Website are at your sole risk.